|This article needs additional citations for verification. (February 2014)|
|Traded as||NASDAQ: AMAG|
AMAG Pharmaceuticals, Inc. is a United States pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company is a publicly traded company on NASDAQ under the symbol "AMAG".
AMAG Pharmaceuticals Inc. operates in the researching, marketing as well as distribution of its drugs. The areas that the company markets its products include Canada, the European Union, and Switzerland.
Treatments and products
The United States
The company's research and tests focus on iron deficiency anemia and related intravenous drugs. In June 2009, the company's main product Ferumoxytol, which is an oral medication used on adult patients with chronic kidney disease, was approved by US Food and Drug Administration (FDA). The drug was estimated by the company to bring a revenue of $71.5 million in 2013 to the company.
In December 2011, the company's product for IDA, Feraheme, was approved for use in treating both dialysis and non-dialysis dependent chronic kidney disease (CKD) patients. At the same year, the drug was also approved to reach Canadian market as a therapy for IDA adult patients.
In August 2013, the company received a new U.S. patent for ferumoxytol, expiring in 2020.
- "AMAG Pharmaceuticals Announces Issuance of New U.S. Patent for Ferumoxytol".